Esperion Therapeutics News, Esperion Therapeutics Quote, ESPR Quote

Esperion Therapeutics (NQ:ESPR) Delayed: 2.73 -0.04 (1.44%)

Prev. Close

$2.77

Today 6M 1Y 5Y

Open

$2.72

52 Wk High

$30.41

52 Wk Low

$9.40

Day High

$2.77

Day Low

$2.64

P/E

N/A

EPS

$-21.87

Volume

6,372,028

Friends, Peers and Foes (?): KKR, TVTX, VRCA, ABBV, AMGN (more...)

ALERTS | RSS

Mar 3, 2026 07:03 AM Form 8-K Esperion Therapeutics, For: Mar 02
Mar 3, 2026 06:00 AM Esperion to acquire Corstasis for $75 million plus milestones
Mar 3, 2026 06:00 AM Esperion Therapeutics and Corstasis Therapeutics Announce Esperion’s Definitive Agreement to Acquire Corstasis, Expanding Its Cardiovascular Franchise with Enbumyst™ (bumetanide nasal spray)
Feb 24, 2026 08:00 AM Esperion to Report Fourth Quarter and Full Year 2025 Financial Results on March 10
Feb 18, 2026 08:00 AM Esperion to Participate in The 2026 Citizens Life Sciences Conference
Feb 17, 2026 08:00 AM Esperion settles with fifth generic drug maker over cholesterol patents
Feb 17, 2026 08:00 AM Esperion Reaches Settlement Agreement with Fifth ANDA Filer Not to Market Generic Version of NEXLETOL® (bempedoic acid) & NEXLIZET® (bempedoic acid & ezetimibe) Prior to April 19, 2040
Feb 17, 2026 08:00 AM Esperion Reaches Settlement Agreement with Fifth ANDA Filer Not to Market Generic Version of NEXLETOL® (bempedoic acid) & NEXLIZET® (bempedoic acid & ezetimibe) Prior to April 19, 2040
Feb 17, 2026 08:00 AM Esperion Reaches Settlement Agreement with Fifth ANDA Filer Not to Market Generic Version of NEXLETOL® (bempedoic acid) & NEXLIZET® (bempedoic acid & ezetimibe) Prior to April 19, 2040
Feb 11, 2026 04:30 PM Esperion Announces Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)

Entities mentioned with ESPR

View All Entities